KR20070085439A - 인플루엔자 м2 단백질에 대한 인간 모노클로날 항체 및그의 제조 및 사용 방법 - Google Patents

인플루엔자 м2 단백질에 대한 인간 모노클로날 항체 및그의 제조 및 사용 방법 Download PDF

Info

Publication number
KR20070085439A
KR20070085439A KR1020077011773A KR20077011773A KR20070085439A KR 20070085439 A KR20070085439 A KR 20070085439A KR 1020077011773 A KR1020077011773 A KR 1020077011773A KR 20077011773 A KR20077011773 A KR 20077011773A KR 20070085439 A KR20070085439 A KR 20070085439A
Authority
KR
South Korea
Prior art keywords
antibody
human
pta
influenza virus
antibodies
Prior art date
Application number
KR1020077011773A
Other languages
English (en)
Korean (ko)
Inventor
신이찌로 가또
롱팡 왕
Original Assignee
기린 비루 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 기린 비루 가부시키가이샤 filed Critical 기린 비루 가부시키가이샤
Publication of KR20070085439A publication Critical patent/KR20070085439A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
KR1020077011773A 2004-12-06 2005-12-05 인플루엔자 м2 단백질에 대한 인간 모노클로날 항체 및그의 제조 및 사용 방법 KR20070085439A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63384604P 2004-12-06 2004-12-06
US60/633,846 2004-12-06
US72419805P 2005-10-06 2005-10-06
US60/724,198 2005-10-06

Publications (1)

Publication Number Publication Date
KR20070085439A true KR20070085439A (ko) 2007-08-27

Family

ID=36578283

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077011773A KR20070085439A (ko) 2004-12-06 2005-12-05 인플루엔자 м2 단백질에 대한 인간 모노클로날 항체 및그의 제조 및 사용 방법

Country Status (9)

Country Link
US (1) US8124091B2 (fr)
EP (2) EP2295465B1 (fr)
JP (1) JP4881874B2 (fr)
KR (1) KR20070085439A (fr)
CN (1) CN101072795B (fr)
AU (1) AU2005313026B2 (fr)
CA (1) CA2585104A1 (fr)
TW (1) TWI377212B (fr)
WO (1) WO2006061723A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8753691B2 (en) * 1999-06-01 2014-06-17 American Silver, Llc Antiviral colloidal silver composition
KR20100097691A (ko) * 2007-11-12 2010-09-03 테라클론 사이언시스, 아이엔씨. 인플루엔자의 치료 및 진단을 위한 조성물 및 방법
AU2008321026B2 (en) * 2007-11-13 2014-01-16 The Scripps Research Institute Production of cytotoxic antibody-toxin fusion in eukaryotic algae
EP2065398A1 (fr) 2007-11-29 2009-06-03 Cytos Biotechnology AG Anticorps spécifiques à la nicotine monoclonale humaine
US8658180B2 (en) * 2008-08-15 2014-02-25 Mark A. Miller Vaccines against influenza virus
TWI444195B (zh) * 2008-10-08 2014-07-11 Pokka Corp Anti-avian influenza virus agents and products containing anti-avian influenza virus agents
EP2346529B1 (fr) * 2008-11-12 2016-02-10 Theraclone Sciences, Inc. Immunogènes peptidiques m2e humains
TWI473621B (zh) * 2008-11-12 2015-02-21 Theraclone Sciences Inc 供治療和診斷流感用之組成物和方法
CN101402677A (zh) * 2008-11-19 2009-04-08 中国人民解放军军事医学科学院微生物流行病研究所 一种四分肽及其应用
CA2745598A1 (fr) * 2008-12-04 2010-06-10 Intercell Ag Anticorps specifiques de m2 de la grippe totalement humains
WO2010110737A1 (fr) * 2009-03-23 2010-09-30 Temasek Life Sciences Laboratory Limited Anticorps monoclonal dirigé contre un domaine conservé du polypeptide m2e dans des virus de la grippe
JP2012527473A (ja) * 2009-05-20 2012-11-08 セラクローン サイエンシーズ， インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
AU2010259533B2 (en) 2009-06-11 2015-03-12 Kyowa Kirin Co., Ltd. Process for production of protein
CN102120759B (zh) * 2010-01-07 2015-08-12 北京英诺泰生物技术有限公司 一种多肽及其衍生物与应用
EP2552490A4 (fr) * 2010-03-26 2013-12-18 Emergent Product Dev Gaithersburg Inc Ectodomaines de la protéine de matrice 2 de la grippe, système d'expression, et leurs utilisations
WO2011123781A1 (fr) 2010-04-02 2011-10-06 Idexx Laboratories, Inc. Détection du virus de l'immunodéficience féline
US20130137083A1 (en) * 2010-04-16 2013-05-30 National Institues of Health a government agency Detection of H5N1 Influenza Infection
PT2653540T (pt) 2010-12-15 2018-02-27 Kyowa Hakko Kirin Co Ltd Processo de produção de proteínas
JP2014509591A (ja) * 2011-03-15 2014-04-21 セラクローン サイエンシーズ， インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
EP2914283B1 (fr) * 2012-11-05 2020-05-20 Georgia State University Research Foundation, Inc. Vaccin universel contre la grippe à base de protéines m2e multiples hétérologues
CA2928035A1 (fr) 2012-12-27 2014-07-03 Massachusetts Eye & Ear Infirmary Traitement de la rhinosinusite par des inhibiteurs de glycoproteine p
CN103901202B (zh) * 2014-04-04 2015-08-12 中国人民解放军成都军区疾病预防控制中心 基于共有表位甲型流感病毒抗体通用型竞争性elisa检测方法
WO2017123933A1 (fr) 2016-01-15 2017-07-20 Massachusetts Eye And Ear Infirmary Glycoprotéine p sécrétée utilisée comme biomarqueur non invasif de la rhinosinusite chronique
CN108517315B (zh) * 2018-03-30 2019-06-04 四川迈克生物新材料技术有限公司 抗人IgM单克隆抗体、其杂交瘤细胞株及应用
CN109022366A (zh) * 2018-08-16 2018-12-18 江南大学 一株分泌抗左旋咪唑单克隆抗体的杂交瘤细胞株及其应用
WO2021201677A1 (fr) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions et procédés ciblant la grippe

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH04503306A (ja) 1989-02-01 1992-06-18 ザ・ジェネラル・ホスピタル・コーポレーション 単純ヘルペスウイルス１型発現ベクター
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0546073B1 (fr) 1990-08-29 1997-09-10 GenPharm International, Inc. production et utilisation des animaux non humains transgeniques capable de produire des anticorps heterologues
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU9166691A (en) 1990-12-20 1992-07-22 Ixsys, Inc. Optimization of binding proteins
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
WO1995013377A1 (fr) 1993-11-12 1995-05-18 Case Western Reserve University Vecteur d'expression episomique destine a la therapie genique humaine
CA2117668C (fr) 1994-03-09 2005-08-09 Izumu Saito Adenovirus recombinant et son mode de production
US5604090A (en) 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
JP3770333B2 (ja) 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
KR100643058B1 (ko) 1996-12-03 2006-11-13 아브게닉스, 인크. 복수의 Ｖн 및 Ｖк 영역을 함유하는 인간 면역글로불린 유전자좌를 갖는 트랜스제닉 포유동물 및 이로부터 생성된 항체
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
ATE312172T1 (de) 1997-08-05 2005-12-15 Vlaams Interuniv Inst Biotech Immunschützendes influenzaantigen und dessen verwendung zur impfung
US6169175B1 (en) 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US6656467B2 (en) 2000-01-27 2003-12-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
EP1391511B1 (fr) 2001-05-11 2008-06-11 Kirin Pharma Kabushiki Kaisha Chromosome humain artificiel contenant le gene a chaine legere de l'anticorps humain lambda
JP2005519619A (ja) * 2002-03-13 2005-07-07 麒麟麦酒株式会社 インフルエンザｍ２タンパク質に対するヒトモノクローナル抗体および上記抗体を作製しかつ利用する方法

Also Published As

Publication number Publication date
CA2585104A1 (fr) 2006-06-15
TWI377212B (en) 2012-11-21
EP2295465B1 (fr) 2013-02-13
CN101072795B (zh) 2014-07-02
US8124091B2 (en) 2012-02-28
WO2006061723A2 (fr) 2006-06-15
US20090196872A1 (en) 2009-08-06
AU2005313026B2 (en) 2011-09-08
WO2006061723B1 (fr) 2007-03-01
EP1819732A2 (fr) 2007-08-22
CN101072795A (zh) 2007-11-14
AU2005313026A1 (en) 2006-06-15
WO2006061723A3 (fr) 2007-01-18
JP2008522610A (ja) 2008-07-03
TW200626614A (en) 2006-08-01
EP2295465A2 (fr) 2011-03-16
EP2295465A3 (fr) 2011-06-22
JP4881874B2 (ja) 2012-02-22

Similar Documents

Publication Publication Date Title
KR20070085439A (ko) 인플루엔자 м2 단백질에 대한 인간 모노클로날 항체 및그의 제조 및 사용 방법
US20050170334A1 (en) Human monoclonal antibodies to influenza M2 protein and methods of making and using same
EP2734545B1 (fr) Anticorps neutralisant le virus de la grippe a, et leurs utilisations
KR101820987B1 (ko) 클로스트리듐 디피실리 관련 감염 및 질병의 치료를 위한 항체
CN113423733B (zh) 结合tslp的抗体及其用途
KR20040111402A (ko) 인플루엔자 м2 단백질에 대한 인간 모노클로날 항체 및그의 제조 및 사용 방법
JP2008522610A5 (fr)
US10882897B2 (en) Neutralizing anti-influenza binding molecules and uses thereof
CN114933651B (zh) 一株羊驼源纳米抗体及其应用
WO2021237516A1 (fr) Anticorps anti-sars-cov-2 et son utilisation
US8003106B2 (en) Human monoclonal antibodies to influenza M2 protein and methods of making and using same
CN114891097A (zh) 一株羊驼源纳米抗体及其应用
US20240083983A1 (en) Anti-hemagglutinin antibodies and methods of use thereof
CN116829589A (zh) 一种新型结合分子及其应用
WO2023230448A1 (fr) Immunothérapie combinée contre la grippe

Legal Events

Date Code Title Description
N231 Notification of change of applicant
N231 Notification of change of applicant
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
J201 Request for trial against refusal decision
E90F Notification of reason for final refusal
B701 Decision to grant